Literature DB >> 17988642

Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments.

Cindy K Bahler1, Kyle G Howell, Cheryl R Hann, Michael P Fautsch, Douglas H Johnson.   

Abstract

PURPOSE: To determine the effect of latanoprost free acid and prostaglandin E1 (PGE1) on outflow facility in cultured human anterior segments. Clinical studies find prostaglandin treatment increases uveoscleral outflow, but do not agree whether trabecular outflow increases. Cultured anterior segments eliminate the uveoscleral pathway and enable a direct assessment of trabecular outflow.
DESIGN: Laboratory investigation.
METHODS: One anterior segment of an eye pair was placed in perfusion organ culture and received a continuous infusion of drug while the fellow anterior segment received vehicle. Histologic changes were assessed. Zymography and Western blots were used to analyze matrix metalloprotease (MMP) activity. Scleral hydraulic conductivities were measured.
RESULTS: Latanoprost significantly increased outflow facility (67% +/- 11% vs control 6% +/- 10%, P < .001). Facility changes occurred within one hour of receiving drug, reaching a new baseline by 24 hours. Facility changes were reversible, requiring about 48 hours to return to pre-drug values. PGE1 caused less facility change (13% +/- 17% vs control 1% +/- 11%, P = .02). Prostaglandin treated anterior segments had regions of focal detachment and loss of Schlemm canal endothelial cells, with loss of extracellular matrix underlying some areas. MMPs were not consistently increased in Western blots, zymography, or immunohistochemistry. Scleral hydraulic conductivity increased, but not enough to account for total facility increase.
CONCLUSIONS: Prostaglandins increase outflow facility in perfusion organ culture of human anterior segments. MMP activity was not consistently increased, and scleral hydraulic conductivity was not increased sufficiently to account for total facility increase. The histologic changes suggest a direct trabecular meshwork effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988642      PMCID: PMC2745953          DOI: 10.1016/j.ajo.2007.09.001

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  26 in total

1.  Direct matrix metalloproteinase enhancement of transscleral permeability.

Authors:  James D Lindsey; Jonathan G Crowston; Ailinh Tran; Christine Morris; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

2.  Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments.

Authors:  B G Dijkstra; A Schneemann; P F Hoyng
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-10       Impact factor: 4.799

3.  Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility.

Authors:  Hagen Thieme; Christin Schimmat; Galina Münzer; Marianne Boxberger; Michael Fromm; Norbert Pfeiffer; Rita Rosenthal
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

4.  Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells.

Authors:  R N Weinreb; K Kashiwagi; F Kashiwagi; S Tsukahara; J D Lindsey
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-12       Impact factor: 4.799

5.  The effect of cytochalasin D on outflow facility and the trabecular meshwork of the human eye in perfusion organ culture.

Authors:  D H Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-12       Impact factor: 4.799

6.  Increased human scleral permeability with prostaglandin exposure.

Authors:  J W Kim; J D Lindsey; N Wang; R N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-06       Impact factor: 4.799

7.  Prostaglandin FP agonists alter metalloproteinase gene expression in sclera.

Authors:  Robert N Weinreb; James D Lindsey; George Marchenko; Natalia Marchenko; Mila Angert; Alex Strongin
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-12       Impact factor: 4.799

8.  Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.

Authors:  K Sheng Lim; Cherie B Nau; Megan M O'Byrne; David O Hodge; Carol B Toris; Jay W McLaren; Douglas H Johnson
Journal:  Ophthalmology       Date:  2008-05       Impact factor: 12.079

9.  Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics.

Authors:  R F Brubaker; E O Schoff; C B Nau; S P Carpenter; K Chen; A M Vandenburgh
Journal:  Am J Ophthalmol       Date:  2001-01       Impact factor: 5.258

10.  Differential effects of vasodilatory prostaglandins on focal adhesions, cytoskeletal architecture, and migration in human aortic smooth muscle cells.

Authors:  C Bulin; U Albrecht; J G Bode; A-A Weber; K Schrör; B Levkau; J W Fischer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-30       Impact factor: 8.311

View more
  43 in total

1.  Circadian variation of aqueous humor dynamics in older healthy adults.

Authors:  Cherie B Nau; Mehrdad Malihi; Jay W McLaren; David O Hodge; Arthur J Sit
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-11-15       Impact factor: 4.799

2.  [Functional morphology of the outflow pathways of aqueous humor and their changes in open angle glaucoma].

Authors:  E R Tamm
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

Review 3.  Aqueous humor outflow: dynamics and disease.

Authors:  Uttio Roy Chowdhury; Cheryl R Hann; W Daniel Stamer; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

4.  Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats.

Authors:  Jessica E McDonald; Julie A Kiland; Paul L Kaufman; Ellison Bentley; N Matthew Ellinwood; Gillian J McLellan
Journal:  Vet Ophthalmol       Date:  2015-07-16       Impact factor: 1.644

Review 5.  Current understanding of conventional outflow dysfunction in glaucoma.

Authors:  W Daniel Stamer; Ted S Acott
Journal:  Curr Opin Ophthalmol       Date:  2012-03       Impact factor: 3.761

6.  Prostaglandin pathway gene therapy for sustained reduction of intraocular pressure.

Authors:  Román A Barraza; Jay W McLaren; Eric M Poeschla
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

7.  Extracellular release of ATP mediated by cyclic mechanical stress leads to mobilization of AA in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Jianming Qiu; Pratap Challa; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

8.  Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.

Authors:  Karen Y Torrejon; Ellen L Papke; Justin R Halman; Judith Stolwijk; Cula N Dautriche; Magnus Bergkvist; John Danias; Susan T Sharfstein; Yubing Xie
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

9.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 10.  Biological properties of trabecular meshwork cells.

Authors:  Joshua Z Gasiorowski; Paul Russell
Journal:  Exp Eye Res       Date:  2008-08-26       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.